Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Reading miRNAs for Clinical Meaning
Single miRNAs Don’t Say Much, but They May Become Eloquent Biomarkers if We Take Their Testimony in Context
For full access to this article login to GEN Select now.
Overcoming Protein Production Hurdles
Increasing Capabilities Becomes Essential as the Biologics Market Grows Rapidly
- Recombinant antibodies have emerged as dominant players in the biopharma industry despite the copious quantities required for treatment. Although nonantibody biologics are typically produced at much smaller scale, are less complex, and have limited secondary modifications, their production is also fraught with challenges. Not surprisingly overcoming protein-production hurdles was ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.